[1]	Cynthia M, Sumaiya A, Lina B, et al. Pregnancy after cancer:FIGO Best practice advice[J]. Int J Gynaecol Obstet, 2025, 169(3):1119-1126. DOI:10.1002/ijgo.70139. 本文引用 [1]

[2]	You L, Lv Z, Li C, et al. Worldwide cancer statistics of adolescents and young adults in 2019:a systematic analysis of the Global Burden of Disease Study 2019[J]. ESMO Open, 2021, 6(5):100255. DOI:10.1016/j.esmoop.2021.100255. 本文引用 [1]

[3]	Shnorhavorian M, Harlan LC, Smith AW, et al. Fertility preservation knowledge,counseling,and actions among adolescent and young adult patients with cancer:A population-based study[J]. Cancer, 2015, 121(19):3499-3506. DOI:10.1002/cncr.29328. 本文引用 [1]

[4]	中国抗癌协会宫颈癌专业委员会. 子宫颈癌筛查规范(2025年版)[J]. 中国实用妇科与产科杂志, 2025, 41(3):332-337. DOI:10.19538/j.fk2025030115. 本文引用 [1]

[5]	Li S, Hu T, Lv W, et al. Changes in prevalence and clinical characteristics of cervical cancer in the People's Republic of China:a study of 10,012 cases from a nationwide working group[J]. Oncologist, 2013, 18(10):1101-1107. DOI:10.1634/theoncologist.2013-0123. 本文引用 [1]

[6]	Contreras NA, Sabadell J, Verdaguer P, et al. Fertility-sparing approaches in atypical endometrial hyperplasia and endometrial cancer patients:current evidence and future directions[J]. Int J Mol Sci, 2022, 23(5):2531. DOI:10.3390/ijms23052531. 本文引用 [2]

[7]	Navarria I, Usel M, Rapiti E, et al. Young patients with endometrial cancer:how many could be eligible for fertility-sparing treatment[J]. Gynecol Oncol, 2009, 114(3):448-451. DOI:10.1016/j.ygyno.2009.05.038. 本文引用 [1]

[8]

Peng H, Jiang J, Li L, et al. Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment[J]. Gynecol Oncol, 2024, 186:154-160. DOI:10.1016/j.ygyno.2024.04.013. 本文引用 [1]

[9]	Rodolakis A, Scambia G, Planchamp F, et al. ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma[J]. Hum Reprod Open, 2023, 2023(1): hoac057. DOI:10.1093/hropen/hoac057. 本文引用 [1]

[10]	Crafton SM, Cohn DE, Llamocca EN, et al. Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries[J]. Cancer, 2020, 126(6):1217-1224. DOI:10.1002/cncr.32620. 本文引用 [1]

[11]

Hu L, Yang H, Luo H, et al. Age-specific reference ranges and variation of anti-mülerian hormone in healthy Chinese women of reproductive and perimenopausal age:a nationwide population-based prospective multicenter cross-sectional study[J]. Gynecol Endocrinol, 2025, 41(1):2431230. DOI:10.1080/09513590.2024.2431230. 本文引用 [1]

[12]	Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women[J]. Hum Reprod Update, 2014, 20(3):370-385. DOI:10.1093/humupd/dmt062. 本文引用 [2]

[13]	Lie Fong S, Visser JA, Welt CK, et al. Serum anti-müllerian hormone levels in healthy females:a nomogram ranging from infancy to adulthood[J]. J Clin Endocrinol Metab, 2012, 97(12):4650-4655. DOI:10.1210/jc.2012-1440. 本文引用 [1]

[14]	Practice Committee of the American Society for Reproductive Medicine. Fertility evaluation of infertile women:a committee opinion[J]. Fertil Steril, 2021, 116(5):1255-1265. DOI:10.1016/j.fertnstert.2021.08.038. 本文引用 [2]

[15]	Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve:a committee opinion[J]. Fertil Steril, 2020, 114(6):1151-1157. DOI:10.1016/j.fertnstert.2020.09.134. 本文引用 [1]

[16]	Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy[J]. Oncologist, 2006, 11(5):422-434. DOI:10.1634/theoncologist.11-5-422. 本文引用 [1]

[17]	Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte[J]. Hum Reprod, 2003, 18(1):117-121. DOI:10.1093/humrep/deg016. 本文引用 [1]

[18]

Meacham LR, Burns K, Orwig KE, et al. Standardizing risk assessment for treatment-related gonadal insufficiency and infertility in childhood adolescent and young adult cancer:the pediatric initiative network risk stratification system[J]. J Adolesc Young Adult Oncol, 2020, 9(6):662-666. DOI:10.1089/jayao.2020.0012. 本文引用 [1]

[19]	Hussein RS, Khan Z, Zhao Y. Fertility preservation in women:indications and options for therapy[J]. Mayo Clin Proc, 2020, 95(4):770-783. DOI:10.1016/j.mayocp.2019.10.009. 本文引用 [1]

[20]	Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy:a committee opinion[J]. Fertil Steril, 2019, 112(6):1022-1033. DOI:10.1016/j.fertnstert.2019.09.013. 本文引用 [1]

[21]	Hansen KR, Knowlton NS, Thyer AC, et al. A new model of reproductive aging:the decline in ovarian non-growing follicle number from birth to menopause[J]. Hum Reprod, 2008, 23(3):699-708. DOI:10.1093/humrep/dem408. 本文引用 [1]

[22]	ACOG. Female age-related fertility decline. Committee Opinion No. 589[J]. Fertil Steril, 2014, 101(3):633-634. DOI:10.1016/j.fertnstert.2013.12.032. 本文引用 [2]

[23]	Mahajan NK. Optimizing advice and approaches for elective fertility preservation[J]. Best Pract Res Clin Obstet Gynaecol, 2025, 99:102591. DOI:10.1016/j.bpobgyn.2025.102591. 本文引用 [1]

[24]	Emrich NLA, Einenkel R, Färber CM, et al. Ovarian tissue cryopreservation for fertility preservation:a two-decade single-center experience with 451 children and adolescents[J]. Reprod Biol Endocrinol, 2025, 23(1):51. DOI:10.1186/s12958-025-01388-x. 本文引用 [1]

[25]	Su HI, Lacchetti C, Letourneau J, et al. Fertility preservation in people with cancer:asco guideline update[J]. J Clin Oncol, 2025, 43(12):1488-1515. DOI:10.1200/JCO-24-02782. 本文引用 [2]

[26]	Grubliauskaite M, van der Perk MEM, Bos AME, et al. Minimal infiltrative disease identification in cryopreserved ovarian tissue of girls with cancer for future use:a systematic review[J]. Cancers (Basel), 2023, 15(17):4199. DOI:10.3390/cancers15174199. 本文引用 [1]

[27]

Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer:a systematic review and meta-analysis of individual patient-level data[J]. J Clin Oncol, 2018, 36(19):1981-1990. DOI:10.1200/JCO.2018.78.0858. 本文引用 [1]

[28]	Roberts JE, Benoit J, Foong S, et al. Fertility preservation in patients undergoing gonadotoxic treatments:a Canadian Fertility and Andrology Society clinical practice guideline[J]. Reprod Biomed Online, 2024, 48(5):103767. DOI:10.1016/j.rbmo.2023.103767. 本文引用 [1]

[29]	Bai F, Lu Y, Wu K, et al. Protecting effects of gonadotropin-releasing hormone agonist on chemotherapy-induced ovarian damage in premenopausal breast cancer patients:a systematic review and meta-analysis[J]. Breast Care (Basel), 2017, 12(1):48-52. DOI:10.1159/000454983. 本文引用 [1]

[30]

Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer:a systematic review and meta-analysis[J]. JAMA Oncol, 2016, 2(1):65-73. DOI:10.1001/jamaoncol.2015.3251. 本文引用 [1]

[31]	Dolmans MM, Taylor HS, Rodriguez-Wallberg KA, et al. Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy:pros and cons[J]. Fertil Steril, 2020, 114(4):725-738. DOI:10.1016/j.fertnstert.2020.08.011. 本文引用 [1]

[32]

Hwang JH, Yoo HJ, Park SH, et al. Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with (postoperative or primary) pelvic radiotherapy[J]. Fertil Steril, 2012, 97(6):1387-1393.e932. DOI:10.1016/j.fertnstert.2012.02.052. 本文引用 [1]

[33]	Buonomo B, Multinu F, Casarin J, et al. Ovarian transposition in patients with cervical cancer prior to pelvic radiotherapy:a systematic review[J]. Int J Gynecol Cancer, 2021, 31(3):360-370. DOI:10.1136/ijgc-2020-001774. 本文引用 [1]

[34]	Perri T, Ben-Baruch G, Davidson T, et al. Use of titanium spiral tacks for long-term oophoropexy before pelvic irradiation[J]. Int J Gynecol Cancer, 2014, 24(6):1133-1136. DOI:10.1097/IGC.0000000000000146. 本文引用 [1]

[35]	Morice P, Juncker L, Rey A, et al. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination[J]. Fertil Steril, 2000, 74(4):743-748. DOI:10.1016/s0015-0282(00)01500-4. 本文引用 [1]

[36]	Schuurman T, Zilver S, Samuels S, et al. Fertility-sparing surgery in gynecologic cancer:a systematic review[J]. Cancers (Basel), 2021, 13(5):1008. DOI:10.3390/cancers13051008. 本文引用 [1]

[37]	Morice P, Scambia G, Abu-Rustum NR, et al. Fertility-sparing treatment and follow-up in patients with cervical cancer,ovarian cancer,and borderline ovarian tumours:guidelines from ESGO,ESHRE,and ESGE[J]. Lancet Oncol, 2024, 25(11):e602-e610. DOI:10.1016/S1470-2045(24)00262-6. 本文引用 [3]

[38]	Dargent D, Franzosi F, Ansquer Y, et al. La trachélectomie élargie,risque de rechute plaidoyer pour un protocole de décision partagée[J]. Bull Cancer, 2002, 89(12):1027-1030. 本文引用 [1]

[39]	Šimják P, Cibula D, Pařízek A, et al. Management of pregnancy after fertility-sparing surgery for cervical cancer[J]. Acta Obstet Gynecol Scand, 2020, 99(7):830-838. DOI:10.1111/aogs.13917. 本文引用 [1]

[40]	程文俊. 卵巢恶性肿瘤生育力保存问题[J]. 中国实用妇科与产科杂志, 2024, 40(11):1082-1086.DOI:10.19538/j.fk2024110107. 本文引用 [1]

[41]	Kyrgiou M, Athanasiou A, Kalliala IEJ, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease[J]. Cochrane Database Syst Rev, 2017, 11(11):CD012847. DOI:10.1002/14651858.CD012847. 本文引用 [1]

[42]	Nitecki R, Floyd J, Lamiman K, et al. Outcomes of the first pregnancy after fertility-sparing surgery for early-stage cervical cancer[J]. Obstet Gynecol, 2021, 138(4):565-573. DOI:10.1097/AOG.0000000000004532. 本文引用 [1]

[43]	Plante M. Vaginal radical trachelectomy:an update[J]. Gynecol Oncol, 2008, 111(2 Suppl):S105-S110. DOI:10.1016/j.ygyno.2008.07.020. 本文引用 [1]

[44]	Peccatori FA, Azim HA, Orecchia R, et al. Cancer, pregnancy and fertility:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol, 2013, 24(6):vi160-vi170. DOI:10.1093/annonc/mdt199. 本文引用 [1]

[45]	La Marca A, Pati M, Orvieto R, et al. Serum anti-müllerian hormone levels in women with secondary amenorrhea[J]. Fertil Steril, 2006, 85(5):1547-1549. DOI:10.1016/j.fertnstert.2005.10.057. 本文引用 [1]

[46]	盛超, 王志坚. 优化妊娠间隔改善妊娠结局[J]. 中国实用妇科与产科杂志, 2023, 39(6):581-584.DOI:10.19538/j.fk2023060102. 本文引用 [1]